Key result
The vasoconstrictor angiotensin was preferred over the vasodilator tolazoline for increasing diagnostic information during pharmacoangiography of bone and soft-tissue tumors.
Why the study?
Does angiotensin improve diagnostic information on angiography compared to tolazoline in patients with bone and soft-tissue tumors?
Does angiotensin improve diagnostic information on angiography compared to tolazoline in patients with bone and soft-tissue tumors?
Angiotensin (10-15 mcg) is preferred over tolazoline for increasing diagnostic information during angiography of bone and soft-tissue tumors.
Answers are grounded in this paper and cite their sources.
Angiotensin may be preferred in tumor pharmacoangiography; leaves open need for randomized confirmation before practice change.
The pharmacoangiographic effect of a vasoconstrictor (angiotensin) and a vasodilator (tolazoline) was compared in 18 patients with bone and soft-tissue tumors. Angiotensin was found to be the drug of choice in increasing diagnostic information on angiography. Ten to 15 mug of angiotensin seems to be a convenient dose in the axillary, iliac, and femoral arteries.
No takes yet. Share an insight, caveat, or question.
Ekelund et al. (1977) studied this question. The vasoconstrictor angiotensin was preferred over the vasodilator tolazoline for increasing diagnostic information during pharmacoangiography of bone and soft-tissue tumors.
Synapse has enriched 10 related papers. Consider them for comparative context: